NewAmsterdam Pharma Co N.V. (NAMS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, NewAmsterdam Pharma reported revenue of $22.5M, down 50.6% from $45.6M the year before. Net income was -$203.8M (a -905.7% net margin), or -$1.72 per diluted share. Operating margin was -1002.9%. Operating activities generated -$147.8M of cash, leaving -$148.0M of free cash flow. At fiscal year end, NewAmsterdam Pharma held $769.3M in total assets against $85.9M in total liabilities, including $490.0M of cash and equivalents.
Open the full interactive NewAmsterdam Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
NewAmsterdam Pharma Key Stats
| Share Price | $20.19 |
|---|---|
| Market Cap | $2.49B |
| Revenue YoY Growth | -50.6% |
| 52-Week Range | $20.19 – $41.45 |
| Shares Outstanding | 123.4 million (basic, 2026 Q2) |
NewAmsterdam Pharma Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $14.1M | $45.6M | $22.5M |
| Operating Income | -$183.0M | -$176.3M | -$225.7M |
| Pre-Tax Income | -$176.9M | -$241.6M | -$203.8M |
| Income Tax | $27,000 | -$1,000 | — |
| Net Income | -$176.9M | -$241.6M | -$203.8M |
| Diluted EPS | -$2.15 | -$2.56 | -$1.72 |
NewAmsterdam Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $348,000 | $32,000 | $3.0M | $3.7M |
| Net Income | -$72.0M | -$74.9M | -$48.4M | -$64.1M |
| Diluted EPS | -$0.61 | -$0.63 | -$0.40 | -$0.52 |
NewAmsterdam Pharma Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | — | $771.7M | $490.0M |
| Current Assets | $346.8M | $863.4M | $675.7M |
| Total Assets | $347.1M | $864.6M | $769.3M |
| Current Liabilities | $49.9M | $106.9M | $85.8M |
| Total Liabilities | $58.7M | $107.1M | $85.9M |
| Shareholders' Equity | $288.4M | $757.5M | $683.4M |
NewAmsterdam Pharma Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$141.2M | -$158.6M | -$147.8M |
| Cash From Investing | -$24,000 | -$62.8M | -$174.9M |
| Cash From Financing | $8.9M | $659.5M | $29.5M |
| Free Cash Flow | -$141.2M | -$159.2M | -$148.0M |
Figures from NewAmsterdam Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full NewAmsterdam Pharma financials page for every line item.
NewAmsterdam Pharma Company Profile
| Ticker | NAMS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Narrden, Netherlands |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001936258 |
Frequently Asked Questions
What was NewAmsterdam Pharma's revenue in fiscal 2025?
NewAmsterdam Pharma (NAMS) reported revenue of $22.5M for fiscal 2025.
What is NewAmsterdam Pharma's annual revenue history?
NewAmsterdam Pharma's annual revenue by fiscal year: 2023: $14.1M; 2024: $45.6M; 2025: $22.5M.
What was NewAmsterdam Pharma's net income in fiscal 2025?
NewAmsterdam Pharma reported net income of -$203.8M for fiscal 2025.
What was NewAmsterdam Pharma's earnings per share (EPS) in fiscal 2025?
NewAmsterdam Pharma's diluted EPS was -$1.72 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did NewAmsterdam Pharma generate in fiscal 2025?
NewAmsterdam Pharma generated -$148.0M of free cash flow in fiscal 2025.
What was NewAmsterdam Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), NewAmsterdam Pharma reported revenue of $3.7M.
How many shares of NewAmsterdam Pharma are outstanding?
NewAmsterdam Pharma reported a weighted average of 123.4 million basic shares outstanding in 2026 Q2.
What is NewAmsterdam Pharma's market cap?
Based on its latest closing price, NewAmsterdam Pharma (NAMS) has a market capitalization of about $2.49B.
When does NewAmsterdam Pharma's fiscal year end?
NewAmsterdam Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is NewAmsterdam Pharma headquartered?
NewAmsterdam Pharma lists its business address in Narrden, Netherlands in its SEC filings.